Literature DB >> 17404160

Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice.

Yasuhide Asaumi1, Yutaka Kagaya, Morihiko Takeda, Nobuhiro Yamaguchi, Hiroko Tada, Kenta Ito, Jun Ohta, Takashi Shiroto, Kunio Shirato, Naoko Minegishi, Hiroaki Shimokawa.   

Abstract

BACKGROUND: Erythropoietin (Epo) receptors (EpoRs) are expressed in the heart. We have recently demonstrated that the endogenous Epo-EpoR system plays an important protective role in myocardial ischemia in mice and humans. In the present study, we tested our hypothesis that the endogenous Epo-EpoR system in nonhematopoietic cells also plays a protective role against pressure overload-induced cardiac dysfunction in vivo. METHODS AND
RESULTS: Transgene-rescued EpoR-null mutant mice (EpoR-/-(rescued)) that express EpoR exclusively in the hematopoietic cells were subjected to transverse aortic constriction (TAC). At 1 week after TAC, left ventricular weight and lung weight were significantly increased in EpoR-/-(rescued) mice compared with wild-type mice, although the fibrotic area was comparably increased after TAC in the 2 genotypes. In the EpoR-/-(rescued) mice with TAC, left ventricular end-diastolic diameter was significantly increased, left ventricular fractional shortening was significantly decreased, and survival rate was significantly decreased compared with wild-type mice with TAC. Phosphorylation of STAT3 at 5 hours and 1 week after TAC and that of p38 at 5 hours after TAC were significantly increased in wild-type mice but not in EpoR-/-(rescued) mice. Vascular endothelial growth factor protein expression and capillary density in left ventricular myocardium were significantly decreased in EpoR-/-(rescued) mice with TAC compared with wild-type mice with TAC.
CONCLUSIONS: These results suggest that the endogenous Epo-EpoR system in the nonhematopoietic cells plays an important protective role against pressure overload-induced cardiac dysfunction in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404160     DOI: 10.1161/CIRCULATIONAHA.106.659037

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Erythropoietin receptor response circuits.

Authors:  Don M Wojchowski; Pradeep Sathyanarayana; Arvind Dev
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

2.  Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents.

Authors:  Terumasa Hayashi; Tomonori Kimura; Keiko Yasuda; Yoshitsugu Obi; Koichi Sasaki; Kenichiro Iio; Kenro Miyasato; Taro Kamimura; Harumi Kitamura; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2012-10-26       Impact factor: 2.801

3.  Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice.

Authors:  Kazutaka Ueda; Hiroyuki Takano; Yuriko Niitsuma; Hiroshi Hasegawa; Raita Uchiyama; Toru Oka; Masaru Miyazaki; Haruaki Nakaya; Issei Komuro
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

Review 4.  Effects of erythropoietin on the bone microenvironment.

Authors:  S J McGee; A M Havens; Y Shiozawa; Y Jung; R S Taichman
Journal:  Growth Factors       Date:  2011-11-28       Impact factor: 2.511

5.  Activation of mitochondrial function and Hb expression in non-haematopoietic cells by an EPO inducer ameliorates ischaemic diseases in mice.

Authors:  Pei-Lun Hsu; Lin-Yea Horng; Kang-Yung Peng; Chia-Ling Wu; Hui-Ching Sung; Rong-Tsun Wu
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 6.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 7.  Raves and risks for erythropoietin.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang
Journal:  Cytokine Growth Factor Rev       Date:  2008-03-04       Impact factor: 7.638

8.  Darbepoetin alfa exerts a cardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activation of the PI3K/Akt and STAT3 pathways.

Authors:  Weike Mao; Chikao Iwai; Jiahao Liu; Shey-Shing Sheu; Michael Fu; Chang-Seng Liang
Journal:  J Mol Cell Cardiol       Date:  2008-05-27       Impact factor: 5.000

Review 9.  Anemia and the potential role of erythropoiesis-stimulating agents in heart failure.

Authors:  Haroon A Faraz; Syed F Zafar; Jalal K Ghali
Journal:  Curr Heart Fail Rep       Date:  2008-06

Review 10.  Erythropoietin and oxidative stress.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Curr Neurovasc Res       Date:  2008-05       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.